Physician profile
Michael D Jordan
NPI 1851512875
$3,618.03
in general payments reported to CMS, 2019-2025
34 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $789 · 2020: $492 · 2021: $302 · 2022: $288 · 2023: $422 · 2024: $1,210 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020 · Travel and Lodging: $700 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,020.09 |
| Travel and Lodging | $699.97 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,083.85 | 2023-2025 | Aquabeam System, Aquabeam Robotic System |
| Astellas Pharma US INC | $458.78 | 2019-2023 | Myrbetriq |
| Pfizer INC. | $284.23 | 2019-2025 | |
| Endo Pharmaceuticals INC. | $202.95 | 2019-2023 | Xiaflex, Aveed |
| Janssen Biotech, INC. | $195.67 | 2019-2024 | Akeega, Erleada |
| Antares Pharma, INC. | $146.27 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Axonics, INC. | $126.22 | 2020-2024 | Axonics |
| Coloplast Corp | $105.04 | 2019-2024 | Speedicath |
| Merck Sharp & Dohme LLC | $91.68 | 2021-2025 | Lynparza, Welireg, Keytruda |
| Myovant Sciences INC. | $90.77 | 2021-2022 | |
| Abbvie INC. | $69.43 | 2020-2023 | |
| Teleflex LLC | $69.18 | 2022 | |
| Sumitomo Pharma America, INC. | $57.46 | 2023-2025 | Orgovyx |
| Dornier Medtech America, INC | $50.83 | 2023 | Dornier Medtech |
| Boston Scientific Corporation | $49.72 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar Pharmaceuticals, INC. | $49.08 | 2019 | |
| Ferring Pharmaceuticals INC. | $45.75 | 2019 | |
| Dendreon Pharmaceuticals LLC | $45.14 | 2019-2023 | Provenge |
| Allergan, INC. | $43.70 | 2019-2021 | |
| Progenics Pharmaceuticals, INC. | $43.38 | 2023 | Pylarify |
| 180 Medical, INC. | $42.14 | 2019-2022 | |
| Convatec INC. | $40.70 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $32.64 | 2022-2023 | Seglentis |
| Hollister Incorporated | $29.23 | 2023 | Vapro Pocket, Vapro Plus Pocket, Infyna Chic |
| Telix Pharmaceuticals | $25.56 | 2023 | Illuccix |
| Urogen Pharma, INC. | $24.96 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $19.13 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Olympus America INC. | $18.98 | 2024 | Itind System |
| Accord Healthcare, INC. | $17.30 | 2022 | |
| Tolmar, INC. | $16.46 | 2023 | |
| Clarus Therapeutics INC. | $15.35 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.40 | 2019 | |
| Medtronic USA, INC. | $12.05 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.